Johnson & Johnson (NYSE:JNJ) is set to report its Q2 2018 earnings on July 17, and we expect the company to post solid numbers, primarily led by continued growth in oncology drug sales, which saw growth of 45% (y-o-y) in the previous quarter. J&J's Imbruvica, Darzalex, and Zytiga have...
Johnson & Johnson (NYSE:JNJ) is set to report its Q2 2018 earnings on July 17, and we expect the company to post solid numbers, primarily led by continued growth in oncology drug sales, which saw growth of 45% (y-o-y) in the previous quarter. J&J's Imbruvica, Darzalex, and Zytiga have...
Share this Article
Recommended